This strategic collaboration is the keystone of BioAtla’s long-term plans to address the growing demand for innovative therapeutic products in the China pharmaceutical market.
“BioAtla’s strategy is to broadly pursue novel therapeutic products based on our patented CAB and other proprietary technologies,” said Jay M. Short, Ph.D., president, chief executive officer and chairman of the board of BioAtla.
“China is an immensely important opportunity for CABs and we are excited to be working with Sinobioway with its demonstrated commitment and strong capabilities to execute and to fulfill our mutual goals. We will continue to build upon our drug development experience to pursue the potential of the CAB platform for our collaboration with Sinobioway, as well as for our collaboration with Pfizer and for our portfolio of proprietary CAB product candidates.”
BioAtla believes CABs can facilitate higher dosing, the development of effective, non-immunogenic drugs, and the use of targets that are validated for cancer cells but traditionally considered too prevalent among normal cells to be used safely in current drug therapies.
BioAtla develops novel monoclonal antibody and other protein therapeutic product candidates designed to have more selective targeting, greaterefficacy, and more cost-efficient and predictable manufacturing than traditional antibodies.
By utilizing its proprietary technologies in product design and development, from target discovery to manufacturing and preclinical studies, BioAtla seeks to develop differentiated, patentable therapeutic proteins for its partners and for its internal programs.
BioAtla has over 170 patents issued and pending that cover its platform technologies representing a full complement of therapeutic protein development capabilities.